Entia Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Cash used in financing activities reached the amount of $0 last year.
Cash Flow
| 2012 | -314.59K | -63.32K | 374.36K |
|---|---|---|---|
| 2013 | -766.73K | -64.60K | 855.14K |
| 2014 | -680.28K | -45.46K | 788.32K |
| 2015 | -536.56K | -21.28K | 482.52K |
| 2016 | -715.09K | -7.11K | 774.13K |
| 2019 | 0 | 0 | 0 |
| 2020 | 0 | 0 | 0 |
| 2021 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 |
ERGO Cash Flow Statement (2012 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 0 | 0 | 0 | 0 | 24.13K | 99.46K | 36.88K | 13.08K | 16.63K |
Operating activities | |||||||||
Net income | 0 | 0 | 0 | 0 | -1.39M | -2.26M | -2.29M | -3.10M | -1.26M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 17.69K | 31.99K | 38.04K | 35.99K | 21.52K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 110.01K | 589.61K | 642.89K | 1.29M | 485.40K |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 110.01K | 589.61K | 642.89K | 1.29M | 485.40K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | -875 | 236.68K | -262.60K | -30.72K | -26.12K |
Inventories | 0 | 0 | 0 | 0 | 25.56K | 53 | 43.56K | -15.80K | 17.95K |
Accounts payable | 0 | 0 | 0 | 0 | 412.94K | 553.77K | 0 | 0 | 0 |
Cash generated by operating activities | 0 | 0 | 0 | 0 | -715.09K | -536.56K | -680.28K | -766.73K | -314.59K |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | -7.11K | -21.28K | -45.46K | -64.60K | -17.18K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | -7.11K | -21.28K | -45.46K | -64.60K | -63.32K |
Financing activities | |||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 560.17K | 225K | 700.87K | 327K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | -55.26K | -77.65K | -83.17K | 0 | 0 |
Cash used in financing activities | 0 | 0 | 0 | 0 | 774.13K | 482.52K | 788.32K | 855.14K | 374.36K |
Net Change In Cash | 0 | 0 | 0 | 0 | 51.91K | -75.32K | 62.57K | 23.80K | -3.55K |
Cash at end of period | 0 | 0 | 0 | 0 | 76.05K | 24.13K | 99.46K | 36.88K | 13.08K |